

## **Adequacy of androgen-replacement therapy among patients with PADAM**

**Alexander Pechersky**<sup>1</sup>

<sup>1</sup> St. Petersburg Medical Academy of Post-Graduate Studies, St Petersburg, Russia

**Objectives:** The dose of the preparation of testosterone when conducting androgen-replacement therapy among patients with PADAM should not exceed the average daily production of testosterone among men.

**Methods:** 57 patients with partial androgen deficiency (all patients were older than 40 years old) were studied. In order to verify that these patients don't have prostate cancer a finger rectal exam, a trans-rectal ultrasound exam, and measurements of the level of PSA in the patient were made. All patients received andriol (testosterone of the undecanoate) in the amount of 40 mg one time per day.

**Results:** One month after the beginning of androgen-replacement therapy a normalization was observed in patients who had had reduced levels of common and free testosterone originally. No increase in the level of PSA among the patients was observed.

**Conclusions:** The results attest to the fact that the given dose of the preparation of testosterone was enough. Considering that about half of the mass of undecanoate testosterone is made of undecanoate, while another part of the preparation is lost while it travels through and is absorbed by the liver-intestinal tract, the dose of 40 mg per day of andriol is the closest possible to an ideal dose. Gel preparations of testosterone, meanwhile, would best be given in the amount of 5 mg per day, since absorption of the gel through the skin creates a minimum loss of the content of the preparation.